A Single Arm, Multicenter, Prospective, Open Label, Longitudinal Phase 3 Study of Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) Combined With Magnetic Resonance Imaging (MRI) Compared to Standard of Care (SOC) for the Detection of Prostate Cancer (PCa).
Latest Information Update: 16 Aug 2025
At a glance
- Drugs TLX591 companion diagnostic Telix Pharmaceuticals (Primary)
- Indications Prostate cancer
- Focus Diagnostic use; Registrational
- Acronyms BiPASS
- Sponsors Telix Pharmaceuticals
Most Recent Events
- 22 Jul 2025 According to Telix media release, company has received HREC approval in Australia and filed an IND with the FDA in the U.S.
- 14 Jul 2025 New trial record